Related Experiment Video
Updated: Jul 16, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Use of risperidone in children with epilepsy
Stefan Padial Ferri Holzhausen1, Marilisa Mantovani Guerreiro, Carlos Eduardo Baccin
1Department of Neurology, State University of Campinas, FCM/Unicamp, PO Box 6111, 13083-970 Campinas, SP, Brazil.
Epilepsy & Behavior : E&B
|March 27, 2007
Summary
Risperidone is safe for children with epilepsy and behavioral disorders, showing significant behavior improvement without negatively impacting seizure frequency in most cases. This study supports its use in pediatric epilepsy management.
Area of Science:
- Pediatric Neurology
- Child Psychiatry
- Clinical Pharmacology
Background:
- Atypical antipsychotics are generally considered safe for epilepsy patients.
- Limited research exists on risperidone use in children with epilepsy and behavioral issues.
Purpose of the Study:
- To assess behavior improvement in children with epilepsy and behavioral disorders treated with risperidone.
- To evaluate the impact of risperidone on seizure outcomes in this pediatric population.
Main Methods:
- Prospective study of 54 pediatric patients (aged 2-18) with epilepsy and behavioral disorders.
- Gradual introduction of risperidone with dosage adjusted based on clinical response.
- Seizure exacerbation defined as increased frequency post-risperidone, resolving upon withdrawal.
Main Results:
- Seizure frequency remained unaffected in 94.5% of patients.
- Only 4% experienced seizure exacerbation; one case was inconclusive.
- Significant behavior improvement was observed in 70.4% of patients.
Conclusions:
- Risperidone appears to be a viable treatment option for pediatric patients with epilepsy and psychiatric comorbidities.
- The medication generally does not alter seizure control in this population.
- Behavioral benefits are frequently achieved with risperidone treatment.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...